Subscribe
scotus-istock-482156434-1
renaschild / iStockphoto.com
18 May 2021BiotechnologyMuireann Bolger

SCOTUS declines patents review on Enbrel drug

A  Novartis unit,  Sandoz, has failed to persuade the  US Supreme Court to review two Amgen-owned patents on the rheumatoid arthritis drug  Enbrel (etanercept), preventing the roll-out of any copies in the US until 2029.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Amgen urges Fed Circuit to deny Sandoz petition
27 August 2020   Amgen’s subsidiary Immunex has called on the US Court of Appeals for the Federal Circuit to reject Sandoz’s request for an en banc rehearing of a dispute over biologic Enbrel.
Americas
Sandoz fails in Enbrel patent challenge, but Fed Circuit split
2 July 2020   Amgen has won a key patent victory over Sandoz in a dispute over biologic Enbrel.


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025

More on this story

Americas
Amgen urges Fed Circuit to deny Sandoz petition
27 August 2020   Amgen’s subsidiary Immunex has called on the US Court of Appeals for the Federal Circuit to reject Sandoz’s request for an en banc rehearing of a dispute over biologic Enbrel.
Americas
Sandoz fails in Enbrel patent challenge, but Fed Circuit split
2 July 2020   Amgen has won a key patent victory over Sandoz in a dispute over biologic Enbrel.

More on this story

Americas
Amgen urges Fed Circuit to deny Sandoz petition
27 August 2020   Amgen’s subsidiary Immunex has called on the US Court of Appeals for the Federal Circuit to reject Sandoz’s request for an en banc rehearing of a dispute over biologic Enbrel.
Americas
Sandoz fails in Enbrel patent challenge, but Fed Circuit split
2 July 2020   Amgen has won a key patent victory over Sandoz in a dispute over biologic Enbrel.

More features

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims